-+ 0.00%
-+ 0.00%
-+ 0.00%
EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing
Share
Listen to the news

STOCKHOLM, Aug. 11, 2026 /PRNewswire/ --

EQT Life Sciences is pleased to announce its participation in Vaderis Therapeutics' USD 152 million Series B financing through one of its managed funds, with a USD 17.5 million investment. The financing was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, Perceptive Advisors, Kalehua Capital and existing investors Medicxi and Droia. The proceeds will support Vaderis with capital needs through potential regulatory approval of engasertib, the company's lead program for hereditary hemorrhagic telangiectasia (HHT).

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending